Home › Products › Oncology › Hetronifly 100mg Solution for Infusion
Hetronifly 100mg Solution for Infusion
Salt Composition: SERPLULIMAB
- Manufacturer: INTAS PHARMACEUTICALS LTD
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 100MG
- Prescription Required
- Storage: ⢠Store as per hospital or pharmacy instructions (usually refrigerated). ⢠Protect from light. ⢠Do not freeze. ⢠Keep out of reach of children. ⢠Do not use after expiry.
₹19218.00₹23437.00
Inclusive of all taxes
Product Introduction
Hetronifly 100mg Solution for Infusion contains Serplulimab, a monoclonal antibody classified as an immunotherapy medicine and PD-1 (Programmed Death-1) inhibitor. It is used in treatment of certain advanced cancers by enhancing the body's immune response against tumour cells. Cancer cells often evade immune detection by blocking immune checkpoint pathways. Serplulimab works by targeting the PD-1 receptor on immune cells, enabling the body to recognise and destroy cancer cells more effectively. During treatment, doctors may recommend regular blood tests, organ function monitoring, and imaging scans to assess treatment response and safety. Since this medicine affects the immune system, careful monitoring for immune-related side effects is essential throughout therapy.
Uses
Hetronifly 100mg Solution for Infusion is used for the treatment of: ⢠Certain advanced or metastatic cancers as advised by oncologists. ⢠Cancers that respond to immune checkpoint inhibitor therapy. ⢠Tumours that have progressed after standard treatments.
How it works
Hetronifly works by activating the bodyâs immune defence against cancer cells. It helps by: ⢠Blocking PD-1 receptors that suppress immune response ⢠Allowing immune cells to recognise cancer cells ⢠Enhancing destruction of tumour cells ⢠Slowing cancer progression This restores the immune systemâs natural ability to fight cancer.
Side Effects
Like all immunotherapy medicines, Hetronifly may cause immune-related reactions. Common Side Effects ⢠Fatigue ⢠Fever ⢠Skin rash or itching ⢠Nausea ⢠Loss of appetite ⢠Muscle or joint pain ⢠Diarrhoea Serious Side Effects ⢠Lung inflammation (shortness of breath, cough) ⢠Liver problems (yellowing of skin, dark urine) ⢠Severe diarrhoea or colitis ⢠Hormone gland disorders ⢠Severe allergic reactions Seek medical help immediately if severe symptoms appear.
Expert Tips
⢠Attend all scheduled infusions and follow-ups. ⢠Report new symptoms early, even mild ones. ⢠Stay hydrated and eat balanced meals. ⢠Avoid self-medication during treatment. ⢠Keep regular blood test appointments. ⢠Inform all doctors you are on immunotherapy.
References
- Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody Serplulimab in patients with advanced solid tumours: safety, pharmacokinetics, and preliminary efficacy. Clinical Cancer Research . 2021;27(18):5163â5172.
- Chinese Society of Clinical Oncology. Immune checkpoint inhibitors in oncology practice: clinical guidance and monitoring. CSCO Guidelines . 2022.
- U.S. National Library of Medicine. Serplulimab (anti-PD-1 monoclonal antibody) clinical trial data. ClinicalTrials.gov . https://clinicaltrials.gov
- Tang B, Yan X, Sheng X, et al. Efficacy and safety of Serplulimab in advanced malignancies: emerging immunotherapy evidence. Journal of Immunotherapy . 2022;45(6):245â253.
- National Cancer Institute. Immune checkpoint inhibitors and cancer treatment overview. https://www.cancer.gov
Safety Advice
Pregnancy: Unsafe May harm the unborn baby. Effective contraception is required.
Lungs: Consult Your Doctor Monitor Especially in long-term therapy.
Breastfeeding: Consult Your Doctor Not recommended during treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.